Since enhanced Lnc-Myd88 expression indicated more aggressive tumors and worse clinical outcome in HCC, we proposed that Lnc-Myd88 might be a novel index for clinical diagnosis, and might serve as a potential therapeutic target for HCC. The gene discussed is MYD88; the disease is hepatocellular carcinoma.